Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

Br J Cancer. 2009 Apr 21;100(8):1343-6. doi: 10.1038/sj.bjc.6604977. Epub 2009 Mar 10.


CCAAT/enhancer binding protein alpha (CEBPA) mutations in AML are associated with favourable prognosis and are divided into N- and C-terminal mutations. The majority of AML patients have both types of mutations. We assessed the prognostic significance of single (n=7) and double (n=12) CEBPA mutations among 224 AML patients. Double CEBPA mutations conferred a decisively favourable overall (P=0.006) and disease-free survival (P=0.013). However, clinical outcome of patients with single CEBPA mutations was not different from CEBPA wild-type patients. In a multivariable analysis, only double -- but not single -- CEBPA mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with CEBPA mutations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / pathology
  • CCAAT-Enhancer-Binding Proteins / blood
  • CCAAT-Enhancer-Binding Proteins / genetics*
  • Confidence Intervals
  • DNA Mutational Analysis
  • Disease-Free Survival
  • Genes, Reporter
  • Humans
  • Karyotyping
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Leukocyte Count
  • Luciferases / genetics
  • Mutation*
  • Prognosis
  • Survival Analysis
  • Survivors


  • CCAAT-Enhancer-Binding Proteins
  • CEBPA protein, human
  • Luciferases